陈星，副教授

研究方向：新药先导化合物设计、合成及生物活性研究

电子邮箱：cx1172624338@163.com

教育经历：

(1) 2019/09-2022/06，维多利亚老品牌vic3308，维多利亚老品牌vic3308，博士

(2) 2016/09-2019/06，维多利亚老品牌vic3308，维多利亚老品牌vic3308，硕士

(3) 2009/09-2014/06，维多利亚老品牌vic3308，维多利亚老品牌vic3308，学士

工作经历：

(1) 2024/11-至今，维多利亚老品牌vic3308，药学科学学院，副教授

(2) 2022/07-2024/11，维多利亚老品牌vic3308，公共卫生学院，博士后

科研项目：

（1）维多利亚老品牌vic3308引进人才科研启动经费，0301045203，主持。

（2）维多利亚老品牌vic3308博士后科研启动经费，0301045201，主持。

（3）中国博士后科学基金会，面上项目，2023M730020，主持。

发表论文情况：

(1)Xing Chen*; Yan Lou*; Feilong Zhou; Daxing Shi; Xinhua Liu; Fangbiao Tao.Identificationof novel indolinone derivatives as CTSC inhibitors to treat inflammatory bowel disease bymodulating inflammatory factors,European Journal of Medicinal Chemistry, 2024, 280:116914.

(2)Xing Chen; Swapna Varghese; Zhaoyan Zhang; Juncheng Du; Banfeng Ruan; Jonathan B. Baell; Xinhua Liu.Drug discovery and optimization based on the co-crystal structure of natural product with target,European Journal of Medicinal Chemistry, 2024, 266: 116126.

(3)Yaoyao Yan; Qi Lv; Feilong Zhou; Yujie Jian; Liu Xinhua;Xing Chen; Yong Hu.Discovery of an effective anti-inflammatory agent for inhibiting the activation of NF-κB,Journal of Enzyme Inhibition and Medicinal Chemistry, 2023, 38(1): 2225135.

(4)Xing Chen; Yaoyao Yan; Xiu Cheng; Zhaoyan Zhang; Chuanbiao He; Dan Wu; Dahai Zhao; Xinhua Liu.A novel CDK8 inhibitor with poly-substituted pyridine core: discovery and anti-inflammatory activity evaluation in vivo,Bioorganic Chemistry, 2023, 133: 106402.

(5) Yaoyao Yan*;Xing Chen*; Yun Xiao; Xiaobao Shen; Zhaoyan Zhang; Chuanbiao He; Jing-Bo Shi;Mingming Liu; Xinhua Liu.Discovery and Anti-Inflammatory Activity Evaluation of a Novel CDK8Inhibitor through Upregulation of IL-10 for the Treatment of Inflammatory Bowel Disease In Vivo,Journal of Medicinal Chemistry, 2022, 65(10): 7334-7362.

(6)Xing Chen*; Yaoyao Yan*; Juncheng Du; Xiaobao Shen; Chuanbiao He; Haitao Pan; Jun Zhu;Xinhua Liu.Non-peptidyl non-covalent cathepsin C inhibitoEEr bearing a unique thiophenesubstituted pyridine: Design, structure-activity relationship and anti-inflammatory activity invivo,European Journal of Medicinal Chemistry, 2022, 236: 114368.

(7)Xing Chen*; Yaoyao Yan*; Zhaoyan Zhang; Faming Zhang; Mingming Liu; Leran Du; Haixia Zhang;Xiaobao Shen; Dahai Zhao; Jing Bo Shi; Xinhua Liu. Discovery and In Vivo Anti-inflammatoryActivity Evaluation of a Novel Non-peptidyl Non-covalent Cathepsin C Inhibitor, Journal ofMedicinal Chemistry, 2021, 64(16): 11857-11885.

(8)Xing Chen; Wen-Jian Tang; Jing Bo Shi; Ming Ming Liu; Jing-Xin Liu.Therapeutic strategies for targeting telomerase in cancer.Medicinal Research Reviews, 2020, 40(2): 532-585.

(9) Yang Wang*;Xing Chen*; Yaoyao Yan; Xiaochen Zhu; Mingming Liu; Xinhua Liu.Discovery andSARs of 5-chloro-N4-phenyl-N2-(pyridin-2-yl)pyrimidine-2,4-diamine derivatives as oral availableand dual CDK 6 and 9 inhibitors with potent anti-tumor activity,Journal of Medicinal Chemistry,2020, 63(6): 3327-3347.

(10)Xing Chen; Gao-Feng Zha; Jie Quan Wang; Xin-Hua Liu.Ethenesulfonyl fluoride derivatives as telomerase inhibitors: structure-based design, SAR, and anticancer evaluation in vitro.Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33(1): 1266-1270.